Earlier Diagnosis and Better Treatment Mission Related to the Cohort Programme

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

1800 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-12-19

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Luxembourg Parkinson's Study is an ongoing longitudinal nationwide monocentric observational study. It collects extensive clinical, molecular, genetic, and digital device-based longitudinal data, as well as foreseen post-mortem diagnostic validation (Hipp et al., 2018). The cohort consists of more than 1,600 participants from Luxembourg and the Greater Region, comprising patients with typical PD or atypical parkinsonism - irrespective of disease stage, age, cognitive status, comorbidities, or linguistic background - followed-up annually and age- and sex-matched healthy control subjects followed-up every 4 years. To provide a large, longitudinally followed, and deeply phenotyped set of patients and controls for clinical and fundamental research on PD, the investigators have implemented an open-source digital platform that has been partly harmonized with other international PD cohort studies. This effort is flanked by comprehensive biosampling efforts assuring high quality and sustained availability of body liquids and tissue biopsies (including blood, urine, stool, saliva, hair, skin biopsy and cerebrospinal fluid). All data and samples are stored, curated, and integrated into state-of-the-art data and biobank facilities.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Parkinson's Disease Progression Study

NCT06219629

Parkinson Disease

ACTIVE_NOT_RECRUITING

Progression in Cognitive ADLs in Parkinson's Disease

NCT05806866

Parkinson Disease

UNKNOWN

Behavioural Profiling of Disease-related Cognitive and Motor Impairment in PD

NCT06275633

Parkinson Disease Medication UPDRS +5 more

COMPLETED NA

Performance of the Paragit Sleeve to Measure and Monitor Motor Symptoms in Patients With Parkinson's Disease

NCT06490861

Parkinson Disease

RECRUITING NA

Identification of Risk Factors Parkinson's Disease by Convergence Strategy

NCT03536104

Parkinson Disease

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PD patients

Subjects with neurodegenerative disease or having degenerative parkinsonism (typical PD or atypical parkinsonism)

Observational study with sample and data collection

Intervention Type OTHER

Observational study with sample and data collection

Healthy controls

Gender- and age-matched healthy controls

Observational study with sample and data collection

Intervention Type OTHER

Observational study with sample and data collection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Observational study with sample and data collection

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects with neurodegenerative disease or having Parkinson's disease (typical PD or atypical parkinsonism)
* Subjects of all genders with a full capacity of consent
* Subjects with a limited consent capacity if the legal guardian/authorised representative is in agreement
* Subjects of at least 18 years of age at the time of inclusion

Exclusion Criteria

* Refusal to sign the informed consent
* Limited capacity of consent on the part of the donor, if there is no legally determined guardian/authorised representative, or the latter is not present or does not agree with the inclusion
* Active cancer
* Pregnant women
* Underage subjects of less than 18 years of age
* Refusal to comply with mandatory sample collection
* For invasive procedures, i.e., lumbar puncture and skin biopsy: relevant blood clotting impairment, e.g., anamnestic evidence of frequent or prolonged bleedings.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes